Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Different patients need different needle sizes
Most vaccines should be given via the
intramuscular route into the deltoid or the anterolateral
aspect of the thigh. This optimises the immunogenicity of the vaccine
and minimises adverse reactions at the injection site. Recent studies
have highlighted the importance of administering vaccines
correctly.1-3 Clinical practice needs to reflect
considerations about the right length and gauge of needles used to
ensure that those vaccinated get the immunological benefit of the
vaccines without local side effects.
Injecting a vaccine into the layer of subcutaneous fat, where poor
vascularity may result in slow mobilisation and processing of antigen,
is a cause of vaccine failure1 Traditionally the buttocks were thought to be an appropriate site for
vaccination, but the layers of fat do not contain the appropriate cells
that are necessary to initiate the immune response (phagocytic or
antigen-presenting cells). The antigen may also take longer to reach
the circulation after being deposited in fat, leading to a delay in
processing by macrophages and eventually presentation to the T and B
cells that are involved in the immune response. In addition,
antigens may be denatured by enzymes if they remain in fat for hours or
days. The importance of these factors is supported by the findings that
thicker skinfolds are associated with a lowered antibody response to
vaccines.
1 2
Serious reactions to intramuscular injections are rare; in one
series of 26 294 adults, of whom 46% had received at least one
intramuscular injection, only 48 (0.4%) had a local adverse effect.4 However, subcutaneous injections can cause
abscesses and granulomas.
1 5 6
Muscle is probably spared
the harmful effects of substances injected into it because of its
abundant blood supply.5 Adipose tissue, having much poorer
drainage channels, retains injected material for much longer and is
therefore also more susceptible to its adverse effects.5
In the case of vaccines in which the antigen is adsorbed to an
aluminium salt adjuvant The injection technique and needle size both determine how deep a
substance is injected. Injection technique involves stretching the skin
flat before inserting the needle or pinching a fold of skin before
injection, which may necessitate the use of longer needles. To make
sure the needle reaches the muscle and that vaccine does not seep into
subcutaneous tissue the decision on the size of the needle and
injection site should be made individually for each person. It should
also be based on the person's age, the volume of material to be
administered, and the size of the muscle.9
In a recent study, the thickness of the fat pad above the deltoid
muscle of the upper arm was measured in 220 adults (healthcare workers
presenting for hepatitis B immunisation) using high frequency ultrasonography.1 A wide variation exists in thickness
of the deltoid fat pad, with women having significantly more
subcutaneous fat than men. A standard 5/8 inch (16mm) needle would not
have achieved sufficient penetration for true deltoid intramuscular injection in 17% of men and nearly 50% of women in the study
population.1 For men weighing 59-118 kg and women of 60-90 kg it may be safer to use a 1 inch (25mm) needle. A woman over 90 kg may need a 1.5 inch (38mm) needle.
Healthcare professionals may hesitate to use longer needles on the
grounds that they are likely to cause the patient more discomfort.
However, skeletal muscle has a poor supply of pain fibres compared with
skin and subcutaneous tissue.10
Consideration should be given to needle gauge.11 A wider
bore needle ensures that the vaccine is dissipated over a wider area,
thus reducing the risk of localised redness and
swelling.12
A standard size of needle will not guarantee successful intramuscular
injection in all people. When intramuscular vaccine administration is
needed to ensure optimal immunogenicity and minimise local reactions, a
selection of non-fixed needles (pre-filled syringes that may be
provided with a needle fixed on the barrel) should be available to
allow healthcare professionals to select a length and gauge of needle
appropriate to each patient.
Academic Centre for Travel Medicine and Vaccines, Royal Free
and University College Medical School, London NW3 2PF
(j.zuckerman{at}rfc.ucl.ac.uk)
for example in hepatitis B,2 rabies, and influenza vaccines.3 Compared
with intramuscular administration, subcutaneous injection of hepatitis
B vaccine leads to significantly lower seroconversion rates and more
rapid decay of antibody response.1
such as those for hepatitis A, hepatitis B,
and diphtheria, tetanus, and pertussis vaccines
the intramuscular
route is strongly preferred because superficial administration leads to
an increased incidence of local reactions such as irritation,
inflammation, granuloma formation, and necrosis.
2 7 8
JZ has been given financial support from several vaccine manufacturers for attending conferences, organising educational programmes, and for undertaking research.
| 1. | Poland GA, Borrud A, Jacobson RM, McDermott K, Wollan PC, Brakke D, et al. Determination of deltoid fat pad thickness: implications for needle length in adult immunization. JAMA 1997; 277: 1709-1711[Abstract]. |
| 2. | Shaw Jr FE, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, et al. Effect of anatomic site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7: 425-430[CrossRef][Medline]. |
| 3. |
Groswasser J, Kahn A, Bouche B, Hanquinet S, Perlmuter N, Hessel L.
Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness.
Pediatrics
1997;
100:
400-403 |
| 4. | Greenblatt DJ, Allen M. Intramuscular injection-site complications. JAMA 1978; 240: 524-524. |
| 5. | Michaels L, Poole RW. Injection granuloma of the buttock. Can Med Ass J 1970; 102: 626-628[Medline]. |
| 6. | Haramati N, Lorans R, Lutwin M, Kaleya RN. Injection granulomas: intramuscle or intrafat? Arch Fam Med 1994; 3: 146-148[Abstract]. |
| 7. |
Ipp MM, Gold R, Goldbach M, Maresky DC, Saunders N, Greenberg S, Davy T.
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length.
Pediatrics
1989;
83:
679-682 |
| 8. | American Academy of Pediatrics. Report of the committee on infectious diseases. 24th ed. Washington: AAP, 1997. |
| 9. | Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization. MMWR 1994; 43: RR-1:6. |
| 10. | Greenblatt DJ, Koch-Weser J. Intramuscular injection of drugs. N Engl J Med 1976; 295: 542-546[Medline]. |
| 11. | Salisbury DM, Begg NT, eds. Immunisation against infectious diseases. London: HMSO, 1996:16. |
| 12. | Mayon-White R, Moreton J. Immunizing children. 2nd ed. London: Radcliffe, 1998:28, 43. |
Read all Rapid Responses
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care